Management of Raynaud’s Phenomenon

John D. Pauling

Vasculitis Treatment Update

Keck School of Medicine of USC

K. Ruddy

How do I Recognize and Treat the VEXAS Syndrome?

Cleveland Clinic Rheumatology

P. Grayson

Are There Factors That Can Guide Treatment Decisions in Newly Diagno…

Cleveland Clinic Rheumatology

A. Villa-Forte

ACR Convergence 2024 Highlights: Diagnosis of Giant Cell Arteritis b…

Highlights from ACR Convergence 2024

V. Caceres

Great Debate (PMR/GCA) - Upfront Use of IL-6 Inhibitors

Hospital for Special Surgery

R. Spiera, P. Seo

Giant Cell Arteritis in the Arab Region With a Focus on Jordan

Fatima Al Naimat

Rheumatology Update for the Generalist in 2024

McMaster University Department of Medicine

R. Mirza

Myths and Misconceptions ANCA Associated Vasculitis

RheumNow

M. Putman

Cleveland Clinic Rheumatic Case Studies: 32 y/o Male w/ Inflammatory…

Cleveland Clinic Rheumatology

L. Calabrese, J. Gelfand, C. Oddis, J. Cush, A. Kavanaugh, R. Hajj-Ali

Abstract Discussions: Osteoporotic Fractures in Postmenopausal Women…

RheumNow

J. Pope

What’s Causing the Inflammatory Arthritis & Weight Loss? Why Did a R…

Cleveland Clinic Rheumatology Case Studies

A. Brown

To B or Not to B - CAR-T Cells Enter the Treatment Arena of IMIDS

William Rigby

How Does the Treatment of Behçet’s Disease Differ Based on Disease M…

Cleveland Clinic Rheumatology

G. Hatemi

70 y/o Male With Seropositive RA, ANCA Vasculitis, and ILD: Would An…

Keck School of Medicine of USC

C. Chen

Diagnosis of Giant Cell Arteritis

Houston Methodist DeBakey Heart and Vascular Center

S. To

Is There Still a Role for Conventional Immunosuppressive Agents in A…

Cleveland Clinic Rheumatology

C. Langford

Are 14-3-3 Proteins Important Antigens in Large Vessel Vasculitis?

Cleveland Clinic Rheumatology

L. Calabrese, G. Hoffman

Maintenance Rituximab in ANCA-Associated Vasculitis: Dose, Frequency…

Cleveland Clinic Rheumatology

R. Smith

Complement and ANCA Vasculitis

Cleveland Clinic Rheumatology

A. Brown